Abstract

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jin Seok Kim ... Alexandre Sostelly
Blood | VOL. 136
Jin Seok Kim, et. al.Jin Seok Kim ... Alexandre Sostelly
05 Nov 2020
Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study
Jules Hernández-Sánchez ... Julia Ramos
Blood | VOL. 136
Jules Hernández-Sánchez, et. al.Jules Hernández-Sánchez ... Julia Ramos
05 Nov 2020
Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors
Alexander Röth ... Alexandre Sostelly
Blood | VOL. 136
Alexander Röth, et. al.Alexander Röth ... Alexandre Sostelly
05 Nov 2020
Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors
Alexandre Sostelly ... Talha Munir
Blood | VOL. 136
Alexandre Sostelly, et. al.Alexandre Sostelly ... Talha Munir
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study.
Linda Sundler Björkman ... Bengt Zöller
Blood | VOL. -
Linda Sundler Björkman, et. al.Linda Sundler Björkman ... Bengt Zöller
17 May 2024
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Jennifer A Woyach ... Veerendra Munugalavadla
Blood | VOL. -
Jennifer A Woyach, et. al.Jennifer A Woyach ... Veerendra Munugalavadla
16 May 2024
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni ... Carlo Visco
Blood | VOL. -
Chiara Malinverni, et. al.Chiara Malinverni ... Carlo Visco
16 May 2024
Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.
Jacqueline A Cook ... Andrew J Menssen
Blood | VOL. -
Jacqueline A Cook, et. al.Jacqueline A Cook ... Andrew J Menssen
15 May 2024
View more papers